These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15127307)

  • 1. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients.
    Artuch R; Aracil A; Mas A; Monrós E; Vilaseca MA; Pineda M
    Neuropediatrics; 2004 Apr; 35(2):95-8. PubMed ID: 15127307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.
    Ribaï P; Pousset F; Tanguy ML; Rivaud-Pechoux S; Le Ber I; Gasparini F; Charles P; Béraud AS; Schmitt M; Koenig M; Mallet A; Brice A; Dürr A
    Arch Neurol; 2007 Apr; 64(4):558-64. PubMed ID: 17420319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
    Di Prospero NA; Sumner CJ; Penzak SR; Ravina B; Fischbeck KH; Taylor JP
    Arch Neurol; 2007 Jun; 64(6):803-8. PubMed ID: 17562928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction. Idebenone in the treatment of Friedreich ataxia.
    Pandolfo M
    J Neurol; 2009 Mar; 256 Suppl 1():1-2. PubMed ID: 19283343
    [No Abstract]   [Full Text] [Related]  

  • 5. Idebenone - monograph.
    Altern Med Rev; 2001 Feb; 6(1):83-6. PubMed ID: 11207459
    [No Abstract]   [Full Text] [Related]  

  • 6. Antioxidants and Friedreich's ataxia.
    Fryer MJ
    Lancet; 1999 Oct; 354(9186):1300-1. PubMed ID: 10520661
    [No Abstract]   [Full Text] [Related]  

  • 7. Friedreich's ataxia: idebenone treatment in early stage patients.
    Artuch R; Aracil A; Mas A; Colomé C; Rissech M; Monrós E; Pineda M
    Neuropediatrics; 2002 Aug; 33(4):190-3. PubMed ID: 12368988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
    Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits.
    Geromel V; Darin N; Chrétien D; Bénit P; DeLonlay P; Rötig A; Munnich A; Rustin P
    Mol Genet Metab; 2002; 77(1-2):21-30. PubMed ID: 12359126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic evaluation of idebenone.
    Becker C; Bray-French K; Drewe J
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1437-44. PubMed ID: 20955109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
    Seznec H; Simon D; Monassier L; Criqui-Filipe P; Gansmuller A; Rustin P; Koenig M; Puccio H
    Hum Mol Genet; 2004 May; 13(10):1017-24. PubMed ID: 15028670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-dose idebenone and quality of life in Friedreich ataxia.
    Brandsema JF; Stephens D; Hartley J; Yoon G
    Pediatr Neurol; 2010 May; 42(5):338-42. PubMed ID: 20399388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful idebenone therapy of hypertrophic cardiomyopathy in Friedreich ataxia].
    Kádár K
    Orv Hetil; 2003 Jun; 144(25):1241-4. PubMed ID: 12901180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurophysiological evaluation in children with Friedreich's ataxia.
    Sival DA; du Marchie Sarvaas GJ; Brouwer OF; Uges DR; Verschuuren-Bemelmans CC; Maurits NM; Brunt ER; van der Hoeven JH
    Early Hum Dev; 2009 Oct; 85(10):647-51. PubMed ID: 19775837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
    Parkinson MH; Schulz JB; Giunti P
    J Neurochem; 2013 Aug; 126 Suppl 1():125-41. PubMed ID: 23859348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
    Di Prospero NA; Baker A; Jeffries N; Fischbeck KH
    Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial.
    Mariotti C; Fancellu R; Caldarazzo S; Nanetti L; Di Bella D; Plumari M; Lauria G; Cappellini MD; Duca L; Solari A; Taroni F
    Mov Disord; 2012 Mar; 27(3):446-9. PubMed ID: 22411849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.
    Lynch DR; Perlman SL; Meier T
    Arch Neurol; 2010 Aug; 67(8):941-7. PubMed ID: 20697044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidants and other pharmacological treatments for Friedreich ataxia.
    Kearney M; Orrell RW; Fahey M; Pandolfo M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007791. PubMed ID: 19821439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of idebenone treatment in patients with Friedreich's ataxia by high-pressure liquid chromatography with electrochemical detection.
    Artuch R; Colomé C; Vilaseca MA; Aracil A; Pineda M
    J Neurosci Methods; 2002 Mar; 115(1):63-6. PubMed ID: 11897364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.